Glycated albumin and composite glycemic-lipid indices: Complementary tools for type 2 diabetes diagnosis

Abstract

Glycated albumin (GA) is a promising glycemic biomarker that offers advantages over glycated hemoglobin (HbA1c), especially under conditions that affect red blood cell turnover. In type 2 diabetes (T2DM), disturbances in glucose and lipid metabolism often coexist. This study aimed to evaluate the discriminatory performance of GA, HbA1c, and their composite indices incorporating high-density lipoprotein cholesterol (HDL-C) in a Serbian cohort of participants with established T2DM and controls. A total of 124 adults (including both T2DM patients and healthy controls) were analyzed for GA, HbA1c, glucose, and lipid profiles. Composite indices, namely, GA/HDL-C and HbA1c/HDL-C, were calculated. Logistic regression and receiver operating characteristic (ROC) analyses were used to assess discriminatory performance. GA and HbA1c levels were significantly higher in T2DM patients, while HDL-C levels were lower. Both GA/HDL-C and HbA1c/HDL-C showed strong associations with T2DM. HbA1c exhibited the highest area under the ROC curve (0.966), followed by HbA1c/HDL-C (0.883), GA/HDL-C (0.859), and GA (0.855). The GA/HDL-C index exhibited particularly high specificity (92.06%). GA levels in the control group were consistent with reference values reported in other populations. To our knowledge, this is the first study to report GA data in a Serbian cohort. The findings highlight GA as a useful complementary marker for distinguishing individuals with established T2DM from controls. Composite indices, particularly GA/HDL-C and HbA1c/HDL-C, may provide complementary information for integrated glycemic-lipid assessment.

Keywords

glycated albumin / type 2 diabetes mellitus / HDL-cholesterol / composite glycemic-lipid indices

References

[1] IDF. The diabetes atlas[EB/OL]. (2021-12-06) [2025-03-20]. http://www.diabetesatlas.org.

[2] Dozio E, Di Gaetano N, Findeisen P, et al. Glycated albumin: From biochemistry and laboratory medicine to clinical practice[J]. Endocrine, 2017, 55(3): 682-690. doi: 10.1007/s12020-016-1091-6

[3] Kirkman MS, Sacks DB. Glycated albumin: Added value or redundancy in diabetes care?[J]. Clin Chem, 2022, 68(3): 379-381. doi: 10.1093/clinchem/hvab261

[4] Sacks DB, Arnold M, Bakris GL, et al. Guidelines and recommendations for laboratory analysis in the diagnosis and management of diabetes mellitus[J]. Diabetes Care, 2023, 46(10): e151-e199. doi: 10.2337/dci23-0036

[5] Shimizu I, Kohzuma T, Koga M. A proposed glycemic control marker for the future: Glycated albumin[J]. J Lab Precis Med, 2019, 4: 23. doi: 10.21037/jlpm.2019.05.01

[6] Ueda Y, Matsumoto H. Recent topics in chemical and clinical research on glycated albumin[J]. J Diabetes Sci Technol, 2015, 9(2): 177-182. doi: 10.1177/1932296814567225

[7] Tang M, Berg AH, Zheng H, et al. Glycated albumin and adverse clinical outcomes in patients with CKD: A prospective cohort study[J]. Am J Kidney Dis, 2024, 84(3): 329-338. doi: 10.1053/j.ajkd.2024.02.006

[8] Shin KS, Park MS, Lee MY, et al. Baseline glycated albumin level and risk of type 2 diabetes mellitus in healthy individuals: A retrospective longitudinal observation in Korea[J]. Scand J Clin Lab Invest, 2024, 84(3): 168-173. doi: 10.1080/00365513.2024.2341412

[9] Zendjabil M. Glycated albumin[J]. Clin Chim Acta, 2020, 502: 240-244. doi: 10.1016/j.cca.2019.11.007

[10] Kurtkulagi O, Aktas G, Taslamacioglu Duman T, et al. Correlation between serum triglyceride to HDL cholesterol ratio and blood pressure in patients with primary hypertension[J]. Precision Med Sci, 2022, 11(3): 100-105. doi: 10.1002/prm2.12080

[11] Bilgin S, Aktas G, Atak Tel BM, et al. Triglyceride to high density lipoprotein cholesterol ratio is elevated in patients with complicated type 2 diabetes mellitus[J]. Acta Fac Med Naissensis, 2022, 39(1): 66-73. doi: 10.5937/afmnai39-33239

[12] Kurtkulagi O, Bilgin S, Kahveci GB, et al. Could triglyceride to high density lipoprotein-cholesterol ratio predict hepatosteatosis?[J]. Exp Biomed Res, 2021, 4(3): 224-229. doi: 10.30714/j-ebr.2021370081

[13] Roohk HV, Zaidi AR, Patel D. Glycated albumin (GA) and inflammation: Role of GA as a potential marker of inflammation[J]. Inflamm Res, 2018, 67(1): 21-30. doi: 10.1007/s00011-017-1089-4

[14] Vergès B. Pathophysiology of diabetic dyslipidaemia: Where are we?[J]. Diabetologia, 2015, 58(5): 886-899. doi: 10.1007/s00125-015-3525-8

[15] Yan Z, Xu Y, Li K, et al. Association between high-density lipoprotein cholesterol and type 2 diabetes mellitus: Dual evidence from NHANES database and Mendelian randomization analysis[J]. Front Endocrinol, 2024, 15: 1272314. doi: 10.3389/fendo.2024.1272314

[16] Martagon AJ, Zubirán R, González-Arellanes R, et al. HDL abnormalities in type 2 diabetes: Clinical implications[J]. Atherosclerosis, 2024, 394: 117213. doi: 10.1016/j.atherosclerosis.2023.117213

[17] Kouzuma T, Usami T, Yamakoshi M, et al. An enzymatic method for the measurement of glycated albumin in biological samples[J]. Clin Chim Acta, 2002, 324(1-2): 61-71. doi: 10.1016/S0009-8981(02)00207-3

[18] Fang M, Daya N, Coresh J, et al. Glycated albumin for the diagnosis of diabetes in US adults[J]. Clin Chem, 2022, 68(3): 413-421. doi: 10.1093/clinchem/hvab231

[19] Cheng P, Neugaard B, Foulis P, et al. Hemoglobin A1c as a predictor of incident diabetes[J]. Diabetes Care, 2011, 34(3): 610-615. doi: 10.2337/dc10-0625

[20] Butler AE, English E, Kilpatrick ES, et al. Diagnosing type 2 diabetes using hemoglobin A1c: A systematic review and meta-analysis of the diagnostic cutpoint based on microvascular complications[J]. Acta Diabetol, 2021, 58(3): 279-300. doi: 10.1007/s00592-020-01606-5

[21] Bellia C, Zaninotto M, Cosma C, et al. Definition of the upper reference limit of glycated albumin in blood donors from Italy[J]. Clin Chem Lab Med, 2017, 56(1): 120-125. doi: 10.1515/cclm-2017-0179

[22] Testa R, Ceriotti F, Guerra E, et al. Glycated albumin: Correlation to HbA_1c and preliminary reference interval evaluation[J]. Clin Chem Lab Med, 2017, 55(2): e31-e33. doi: 10.1515/cclm-2016-0512

[23] Selvin E, Warren B, He X, et al. Establishment of community-based reference intervals for fructosamine, glycated albumin, and 1, 5-anhydroglucitol[J]. Clin Chem, 2018, 64(5): 843-850. doi: 10.1373/clinchem.2017.285742

[24] Chume FC, Kieling MH, Freitas PAC, et al. Glycated albumin as a diagnostic tool in diabetes: An alternative or an additional test?[J]. PLoS One, 2019, 14(12): e0227065. doi: 10.1371/journal.pone.0227065

[25] Chume FC, Freitas PAC, Schiavenin LG, et al. Glycated albumin in diabetes mellitus: A meta-analysis of diagnostic test accuracy[J]. Clin Chem Lab Med, 2022, 60(7): 961-974. doi: 10.1515/cclm-2022-0105

[26] Lenters-Westra E, Atkin SL, Kilpatrick ES, et al. Limitations of glycated albumin standardization when applied to the assessment of diabetes patients[J]. Clin Chem Lab Med, 2024, 62(12): 2526-2533. doi: 10.1515/cclm-2024-0591

[27] Hassanein M, Shafi T. Assessment of glycemia in chronic kidney disease[J]. BMC Med, 2022, 20(1): 117. doi: 10.1186/s12916-022-02316-1

[28] Cao C, Hu H, Zheng X, et al. Non-linear relationship between high-density lipoprotein cholesterol and incident diabetes mellitus: A secondary retrospective analysis based on a Japanese cohort study[J]. BMC Endocr Disord, 2022, 22(1): 163. doi: 10.1186/s12902-022-01074-8

[29] Denimal D. Antioxidant and anti-inflammatory functions of high-density lipoprotein in type 1 and type 2 diabetes[J]. Antioxidants (Basel), 2023, 13(1): 57. doi: 10.3390/antiox13010057

[30] Aarsand AK, Díaz-Garzón J, Fernandez-Calle P, et al. The EuBIVAS: Within- and between-subject biological variation data for electrolytes, lipids, urea, uric acid, total protein, total bilirubin, direct bilirubin, and glucose[J]. Clin Chem, 2018, 64(9): 1380-1393. doi: 10.1373/clinchem.2018.288415